Domo Sees Q2 EPS $(0.07)-$(0.11) Vs Vs $(0.1) Est.; Revenue $78.5M-$79.5M Vs $79.73M Est.; FY24 EPS $(0.27)-$(0.39) Vs $(0.34) Est.; Revenue $323M-$330M Vs $325.97M Est.

Business Outlook Based on information available as of May 25, 2023, Domo is providing the following guidance for its second fiscal quarter and full year fiscal 2024: Q2 Fiscal 2024 Revenue is

Business Outlook

Based on information available as of May 25, 2023, Domo is providing the following guidance for its second fiscal quarter and full year fiscal 2024:

Q2 Fiscal 2024

  • Revenue is expected to be in the range of $78.5 million to $79.5 million
  • Non-GAAP net loss per share is expected to be between $0.07 and $0.11 based on 35.9 million weighted-average shares outstanding

Full Year Fiscal 2024

  • Revenue is expected to be in the range of $323.0 million to $330.0 million
  • Non-GAAP net loss per share is expected to be between $0.27 and $0.39 based on 36.1 million weighted-average shares outstanding

We have not reconciled guidance for non-GAAP metrics to their most directly comparable GAAP measures because certain items that impact these measures are not within our control or cannot be reasonably predicted.

Total
0
Shares
Related Posts
Read More

Sight Sciences Announces Presentation Of Phase I Results Of The SAHARA Randomized Controlled Clinical Trial Comparing TearCare To Restasis For The Treatment Of Dry Eye Disease At The American Academy Of Optometry Annual Meeting

Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients'

SGHT